Research Paper Volume 11, Issue 20 pp 8892—8910

TGF-β receptor inhibitor LY2109761 enhances the radiosensitivity of gastric cancer by inactivating the TGF-β/SMAD4 signaling pathway

class="figure-viewer-img"

Figure 1. Relationship between the TGF-β expressions with the overall survival and radioresistance in GC patients. (A) Kaplan-Meier survival curves for high and low mRNA TGF-β1 expression level in GC patients. (B) Kaplan-Meier survival curves for high and low mRNA TGF-β2 expression level in GC patients. (C) Immunohistochemical analysis: representative immunohistochemistry images of the TGF-β1, TGF-β2, SMAD4, E-CA and N-CA expressions in biopsy samples of GC patients. (a) Specimen from a patient whose tumor sample showed a complete response to radiotherapy (radiosensitive GC patient). (b) Specimen from a patient whose tumor sample showed no change after radiotherapy (radioresistant GC patient). Original magnification, ×400. P<0.05.